Format

Send to

Choose Destination
Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13.

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.

Author information

1
St. Michael's Hospital, Division of Cardiac Surgery (S.V.) vermasu@smh.ca.
2
Department of Anesthesia (C.D.M.).
3
Division of Vascular Surgery (M.A.-O.).
4
Department of Surgery, King Saud University, Riyadh, Saudi Arabia (M.A.-O.).
5
Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.).
6
Division of Cardiology (D.F.), University of Toronto, Ontario, Canada.
7
Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany (U.H., J.T.G.).
8
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada (B.Z.).
9
Division of Endocrinology, University of Toronto, Ontario, Canada (B.Z.).

KEYWORDS:

diabetes mellitus peripheral arterial disease; sodium-glucose cotransporter 2

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center